Collaborations

To maximize the potential for our products to make a difference in patients' lives, Alkermes has development and marketing agreements with some of the world's leading pharmaceutical companies.

Amylin Logo 2009

In collaboration with Amylin Pharmaceuticals, Inc., we have developed exenatide once weekly, a Medisorb® formulation of BYETTA® (exenatide) for the treatment of type 2 diabetes. This long-acting release formulation has the potential to provide important therapeutic benefits in a once-weekly dosing regimen.

  • Alkermes is responsible for developing potential long-acting formulations of exenatide.
  • Amylin is responsible for conducting clinical trials, securing regulatory approvals, manufacturing exenatide once weekly for commercial sale and for the sales and marketing of any products resulting from the collaboration.

For more information visit: http://www.amylin.com/


   
Janssen 

We are collaborating with Janssen-Cilag (Janssen), a division of Johnson & Johnson, to market RISPERDAL® CONSTA® (risperidone) Long-Acting Injection, a long-acting injection of the oral medicine RISPERDAL® (risperidone) for the treatment of schizophrenia and bipolar disorder. RISPERDAL CONSTA uses our Medisorb® technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks.

  • Janssen markets RISPERDAL CONSTA in over 60 countries worldwide, including the U.S. and major European markets.
  • Alkermes is responsible for manufacturing RISPERDAL CONSTA.

For more information, visit www.janssen-cilag.com

   
Cilag 

We have an agreement with Cilag GmbH International, a subsidiary of Johnson & Johnson, to commercialize VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence in Russia and other countries in the Commonwealth of Independent States (CIS).

  • Janssen-Cilag, an affiliate company of Cilag GmbH International, is responsible for securing all necessary regulatory approvals and will commercialize VIVITROL in Russia and other countries in the CIS.
  • Alkermes is responsible for manufacturing VIVITROL.

For more information, visit www.janssen-cilag.com

   
Acceleron 

In collaboration with Acceleron Pharma, Inc., we are developing ALKS 6931, a Medifusion(TM) formulation of a TNF receptor-Fc fusion protein for the treatment of rheumatoid arthritis and related autoimmune diseases.

  • Acceleron is responsible for development of up to two selected drug compounds using the Medifusion technology through preclinical studies.
  • Alkermes is responsible for conducting clinical trials, securing regulatory approvals, manufacturing, and commercialization of any products resulting from the Medifusion technology platform.

For more information, visit www.acceleronpharma.com

   

Upcoming Presentations